CA2175081A1 - Vaccin et procede de traitement contre les infections a chlamydia - Google Patents
Vaccin et procede de traitement contre les infections a chlamydiaInfo
- Publication number
- CA2175081A1 CA2175081A1 CA 2175081 CA2175081A CA2175081A1 CA 2175081 A1 CA2175081 A1 CA 2175081A1 CA 2175081 CA2175081 CA 2175081 CA 2175081 A CA2175081 A CA 2175081A CA 2175081 A1 CA2175081 A1 CA 2175081A1
- Authority
- CA
- Canada
- Prior art keywords
- momp
- vaccine
- preparation
- chlamydia
- lps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Vaccin destiné au traitement des infections à chlamydia, constitué d'une préparation de protéine de membrane externe majeure (MOMP) et d'une préparation de lipopolysaccharide (LPS) obtenue à partir d'un organisme porteur de chlamydia. Procédé de traitement et d'immunisation des animaux contre les infections à chlamydia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14763693A | 1993-11-03 | 1993-11-03 | |
US08/147,636 | 1993-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2175081A1 true CA2175081A1 (fr) | 1995-05-11 |
Family
ID=22522314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2175081 Abandoned CA2175081A1 (fr) | 1993-11-03 | 1994-11-02 | Vaccin et procede de traitement contre les infections a chlamydia |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0726775A4 (fr) |
CN (1) | CN1134112A (fr) |
AU (1) | AU701247B2 (fr) |
BR (1) | BR9407986A (fr) |
CA (1) | CA2175081A1 (fr) |
NZ (1) | NZ276874A (fr) |
WO (1) | WO1995012411A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2184132C (fr) * | 1995-09-21 | 2011-03-15 | Kristina J. Hennessy | Vaccin avec adjuvant, pratiquement exempt d'albumine non-hote |
US5972350A (en) * | 1996-05-06 | 1999-10-26 | Bayer Corporation | Feline vaccines containing Chlamydia psittaci and method for making the same |
US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
CA2336534A1 (fr) * | 1998-07-27 | 2000-02-10 | Connaught Laboratories Limited | Antigenes de chlamydia et fragments d'adn correspondants, et utilisations de ceux-ci |
CA2366462C (fr) * | 1998-12-04 | 2011-08-09 | University Of Manitoba | Procedure d'immunisation en deux etapes contre l'infection parchlamydia |
ATE463575T1 (de) * | 1999-12-22 | 2010-04-15 | Aventis Pasteur | Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen |
AU2138601A (en) * | 1999-12-22 | 2001-07-03 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
WO2001046225A2 (fr) * | 1999-12-22 | 2001-06-28 | Aventis Pasteur Limited | Antigenes anti-chlamydia, fragments d'adn correspondants et leurs utilisations |
ES2386386T3 (es) * | 2001-12-12 | 2012-08-20 | Novartis Vaccines And Diagnostics S.R.L. | Inmunización contra Chlamydia trachomatis |
ES2788728T3 (es) | 2010-05-28 | 2020-10-22 | Spixia Biotechnology Ab | Antígeno de la MOMP quimérica, método y uso |
US10688171B2 (en) | 2015-02-10 | 2020-06-23 | Ohio State Innovation Foundation | Chlamydia-activated B cell platforms and methods thereof |
CN108367058A (zh) * | 2015-11-10 | 2018-08-03 | 俄亥俄州创新基金会 | 与加快的体液亲和力相关的方法和组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4271146A (en) * | 1979-09-06 | 1981-06-02 | Seawell Albert C | Methods of using Chlamydia vaccine for preventing and treating bovine and ovine diseases |
-
1994
- 1994-11-02 NZ NZ276874A patent/NZ276874A/en unknown
- 1994-11-02 BR BR9407986A patent/BR9407986A/pt not_active Application Discontinuation
- 1994-11-02 AU AU11297/95A patent/AU701247B2/en not_active Ceased
- 1994-11-02 CA CA 2175081 patent/CA2175081A1/fr not_active Abandoned
- 1994-11-02 EP EP95902425A patent/EP0726775A4/fr not_active Withdrawn
- 1994-11-02 CN CN 94193980 patent/CN1134112A/zh active Pending
- 1994-11-02 WO PCT/US1994/012626 patent/WO1995012411A1/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR9407986A (pt) | 1996-12-03 |
WO1995012411A1 (fr) | 1995-05-11 |
AU701247B2 (en) | 1999-01-21 |
AU1129795A (en) | 1995-05-23 |
EP0726775A4 (fr) | 1999-03-31 |
EP0726775A1 (fr) | 1996-08-21 |
NZ276874A (en) | 1997-11-24 |
CN1134112A (zh) | 1996-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goto et al. | Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties | |
JP2022078317A (ja) | Staphylococcus aureusに対して免疫化するための組成物 | |
ES2374278T3 (es) | Vacuna canina para la protección contra la erliquiosis. | |
Munir et al. | Outer membrane proteins of Brucella abortus vaccinal and field strains and their immune response in buffaloes | |
McLean et al. | Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine | |
Abraham et al. | Inducible immunity to Trichomonas vaginalis in a mouse model of vaginal infection | |
CA2175081A1 (fr) | Vaccin et procede de traitement contre les infections a chlamydia | |
KR20090094393A (ko) | 백신 투여 방법 | |
RU2723046C2 (ru) | Вакцины против Chlamydia sp. | |
Wang et al. | Research progress in live attenuated Brucella vaccine development | |
Prescott et al. | Use of a virulence‐associated protein based enzyme‐linked immunosorbent assay for Rhodococcus equi serology in horses | |
CN102438650A (zh) | 衣原体抗原 | |
Bai et al. | Hollow mesoporous silica nanoparticles as delivery vehicle of foot‐and‐mouth disease virus‐like particles induce persistent immune responses in guinea pigs | |
Zhu et al. | Comparison of immune effects between Brucella recombinant Omp10-Omp28-L7/L12 proteins expressed in eukaryotic and prokaryotic systems | |
CN106103469A (zh) | 突变型葡萄球菌抗原 | |
AU769375B2 (en) | Vaccine formulation | |
DE60218662T2 (de) | Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine | |
JP5661744B2 (ja) | 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用 | |
KR20010075049A (ko) | 성인성질환에 대한 백신 | |
Miao et al. | Enhanced immune response to rabies viruses by the use of a liposome adjuvant in vaccines | |
Parmley et al. | Protective effects of immunization with a recombinant cyst antigen in mouse models of infection with Toxoplasma gondii tissue cysts | |
Erturk et al. | Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection | |
Sandbulte et al. | Evaluation of Chlamydia psittaci subfraction and subunit preparations for their protective capacities | |
Luke et al. | Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi | |
Muñoz et al. | Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |